Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2026)

Tg Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $596000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 79.78% year-over-year to $596000.0 in Q1 2026; TTM through Mar 2026 was $596000.0, a 79.78% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 54.1% from the prior year.
• Other Accumulated Expenses eased to $596000.0 in Q1 2026 per TGTX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.6 million in Q4 2024 and bottomed at $596000.0 in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $1.9 million (2022), against an average of $2.2 million.
• Across the five-year window, Other Accumulated Expenses slumped 93.61% in 2022 and jumped 232.84% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.2 million in 2022, then climbed by 26.52% to $1.5 million in 2023, then jumped by 212.85% to $4.6 million in 2024, then tumbled by 54.1% to $2.1 million in 2025, then slumped by 71.94% to $596000.0 in 2026.
• Per Business Quant, the three latest TGTX Other Accumulated Expenses figures stand at $596000.0 (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025).